News & Updates
Filter by Specialty:
SGLT-2 inhibitors may prevent dementia in adults with T2D
Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.
SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024
Tapinarof safe, efficacious for moderate-to-severe AD in children, adults
Treatment with tapinarof cream 1% once daily demonstrates significant efficacy with a favourable safety profile among adults and children with moderate-to-severe atopic dermatitis (AD), a study has shown.
Tapinarof safe, efficacious for moderate-to-severe AD in children, adults
06 Sep 2024
Dupilumab prevents atopic march progression in children with AD
Use of dupilumab effectively lowers the risk of atopic march progression as opposed to conventional immunomodulatory therapies in paediatric patients with atopic dermatitis (AD), reports a recent study.
Dupilumab prevents atopic march progression in children with AD
06 Sep 2024
Wolbachia-infected male Aedes aegypti mosquito releases stem dengue incidence
Releasing Wolbachia-infected male Aedes (A) aegypti mosquitoes were associated with a reduction in dengue incidence rates, a synthetic control study in Singapore has shown.
Wolbachia-infected male Aedes aegypti mosquito releases stem dengue incidence
06 Sep 2024
Paediatric T2DM: Prevalence of microalbuminuria doubles within 2 years of diagnosis
Data from the Hong Kong Childhood Diabetes Registry (HKCDR) show that 2 years after diagnosis of paediatric type 2 diabetes mellitus (T2DM), approximately 20–65 percent of patients have ≥1 of the following: microalbuminuria (MA), suboptimal glycaemic control, hypertension, or dyslipidaemia.
